Thinking big, Bayer’s Axel Bouchon tackles stem cell field with $225M startup partnered with Versant
Bayer’s Axel Bouchon has struck again.
Less than four months since the Bayer exec struck a deal with CRISPR Therapeutics to launch a gene editing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
